FAQ on Nutriband Inc.'s AVERSA Fentanyl Manufacturing Milestone and Price Target Increase
Summary
What is the significance of Nutriband Inc.’s recent milestone with AVERSA Fentanyl?
The completion of commercial manufacturing and scale-up for AVERSA Fentanyl is a key inflection point for Nutriband, enabling the initiation of clinical supplies production and proceeding with an Investigational New Drug (IND) application for a Phase 1 trial, aimed at reducing the appeal to recreational drug users.
Why was Nutriband Inc.’s price target raised to $15?
Robert LeBoyer of Noble Capital Markets raised the price target to $15 following the successful milestone of AVERSA Fentanyl’s commercial manufacturing and scale-up, viewing the upcoming Phase 1 trial as low risk and noting Nutriband’s adherence to timeline projections.
How does the AVERSA Fentanyl patch work to deter abuse?
AVERSA technology is designed to be incorporated into transdermal patches to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential, though the specific mechanisms are not detailed in the provided content.
When is the NDA submission for AVERSA Fentanyl expected?
The New Drug Application (NDA) submission for AVERSA Fentanyl is expected between late 2025 and early 2026, with full-year sales projected to begin in FY2027.
Who is involved in the development of AVERSA Fentanyl?
Nutriband Inc. is developing AVERSA Fentanyl in partnership with Kindeva, and the project’s progress has been highlighted by Robert LeBoyer, Senior Vice President and Equity Research Analyst at Noble Capital Markets.
What are the projected earnings per share (EPS) for Nutriband in FY2027?
Robert LeBoyer raised his FY2027 EPS forecast for Nutriband to $1.57, citing the company’s adherence to timeline projections and the avoidance of a previously expected Q1 2025 equity raise.
Where can I find more information about Nutriband Inc. and its developments?
More information about Nutriband Inc. can be found on their website at www.Nutriband.com and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB.
What is the regulatory pathway for AVERSA Fentanyl?
The AVERSA program follows the 505(b)(2) regulatory pathway, which requires only a single Phase 1 study aimed at showing reduced appeal to recreational drug users.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 107856